arrow_back Back to App

Equal Costs for Breast Cancer Diagnostic and Screening Exams

New rules ensure insurance plans cannot charge more or impose greater limitations for breast cancer diagnostic exams than for screening exams. This means citizens will not pay more for tests confirming a diagnosis than for routine preventive screenings. These changes take effect from January 1, 2022.
Key points
Insurers cannot charge higher fees (e.g., deductibles, co-pays) for breast cancer diagnostic exams than for screening exams.
Stricter limits (e.g., number of visits) cannot be imposed on diagnostic breast cancer exams compared to screening exams.
The changes also apply to older insurance plans previously exempt from some regulations.
The act does not require replacing screening exams with diagnostic ones, nor does it prohibit insurers from requiring prior authorization for tests.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_S_1067
Sponsor: Sen. Blunt, Roy [R-MO]
Process start date: 2021-04-12
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Access to Breast Cancer Diagnosis Act of 2021

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_S_1067.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2021-04-12.

What are the main provisions?

Key points include:

  • Insurers cannot charge higher fees (e.g., deductibles, co-pays) for breast cancer diagnostic exams than for screening exams.
  • Stricter limits (e.g., number of visits) cannot be imposed on diagnostic breast cancer exams compared to screening exams.
  • The changes also apply to older insurance plans previously exempt from some regulations.
  • The act does not require replacing screening exams with diagnostic ones, nor does it prohibit insurers from requiring prior authorization for tests.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Blunt, Roy [R-MO].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-29.

CATEGORIES

Health